...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
【24h】

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.

机译:非小细胞肺癌患者中表皮生长因子受体酪氨酸激酶结构域的突变及其与临床病理特征的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Somatic tyrosine kinase (TK) domain mutations of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKI's), however their incidence in distinct populations is not clarified. We sequenced exons 18-21 of the EGFR TK domain from 60 Greek and Czech patients, enrolled in an adjuvant chemotherapy trial following total resection for stages I-IIIa disease. Somatic mutations were found in 9/60 patients (15.0%), several being novel. EGFR mutations were more common in Stage I tumors (p = 0.023), they were also more common in women and never smokers; however, no other significant association of clinicopathological features with mutations was found. Median TTP and OS of patients with and without mutations were 13.2 and 40 months compared to 22.9 and 43.2 months, respectively. These differences were not statistically significant. K-ras (5/60, 8%) and EGFR mutations were found to be mutually exclusive. We identified a wide spectrum of somatic EGFR TK mutations reporting a relatively high incidence (15%) in NSCLC patients of Greek and Czech origin. As ethnicity seems to be a factor for the origin of these mutations, further studies in distinct populations are warranted.
机译:表皮生长因子受体(EGFR)基因的体细胞酪氨酸激酶(TK)结构域突变与非小细胞肺癌(NSCLC)对酪氨酸激酶抑制剂(TKI's)的敏感性有关,但是尚不清楚它们在不同人群中的发生率。我们对60名希腊和捷克患者的EGFR TK结构域第18-21外显子进行了测序,参与了I-IIIa期疾病全切除后的辅助化疗试验。在9/60例患者中发现了体细胞突变(15.0%),其中一些是新颖的。 EGFR突变在I期肿瘤中更为常见(p = 0.023),在女性且从不吸烟者中也更为常见。然而,没有发现其他临床病理特征与突变的显着关联。有突变和无突变的患者的中位TTP和OS分别为13.2和40个月,而分别为22.9和43.2个月。这些差异无统计学意义。发现K-ras(5/60,8%)和EGFR突变是互斥的。我们在希腊和捷克血统的NSCLC患者中发现了广泛的体表EGFR TK突变,报道了相对较高的发生率(15%)。由于种族似乎是这些突变起源的一个因素,因此有必要在不同的人群中进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号